With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4677-20-7,4-(2-Bromoethyl)tetrahydropyran,as a common compound, the synthetic route is as follows.
Example 110A Di-tert-butyl [2-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl](2-oxo-2-{6-[2-(tetrahydro-2H-pyran-4-yl)ethoxy]-1,2-benzoxazol-3-yl}ethyl)malonate To a mixture of 150 mg (0.27 mmol) of the compound from Example 99A in 1.5 ml of acetonitrile were added at RT 110 mg (0.80 mmol) of potassium carbonate and 154 mg (0.80 mmol) of 4-(2-bromoethyl)tetrahydro-2H-pyran. The mixture was stirred under reflux for 2 h. After admixing with ice water, the aqueous phase was extracted twice with ethyl acetate. The combined organic phases were dried over magnesium sulphate, filtered and concentrated. The residue was purified by means of column chromatography (40 g of silica gel, mobile phase cyclohexane/ethyl acetate 7:3). 132 mg (68% of theory, purity 92%) of the title compound were obtained. LC/MS (Method 1, ESIpos): Rt=1.51 min, m/z=677 [M+H]+.
4677-20-7 4-(2-Bromoethyl)tetrahydropyran 22637012, aTetrahydropyrans compound, is more and more widely used in various.
Reference£º
Patent; BAYER PHARMA AKTIENGESELLSCHAFT; BECK, Hartmut; LI, Volkhart Min-Jian; CANCHO GRANDE, Yolanda; TIMMERMAN, Andreas; BROHM, Dirk; JOeRIssEN, Hannah; BOGNER, Pamela; GERISCH, Michael; LANG, Dieter; (120 pag.)US2017/121315; (2017); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics